Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomarkers in Clozapine-responding Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2022
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Clozaril
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Extractas Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.
Details : Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.
Product Name : Versacloz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2020
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Extractas Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2018
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : The Ian Douglas Bebensee Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2015
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : The Ian Douglas Bebensee Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 24, 2015
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Technion – Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel
Deal Size : Inapplicable
Deal Type : Inapplicable
Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2012
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Technion – Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2011
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable